Lupin receives tentative approval from USFDA for Generic Rapaflo Capsules

Pharma Major Lupin Limited (Lupin) announced that it has received tentative approval for its Silodosin Capsules, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Allergan Sales, LLC's Rapaflo Capsules, 4 mg and 8 mg.

Lupin's Silodosin Capsules, 4 mg and 8 mg are the AB rated generic equivalent of Allergan Sales, LLC's Rapaflo Capsules, 4 mg and 8 mg. It is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.